Home Cart Sign in  
Chemical Structure| 122520-79-0 Chemical Structure| 122520-79-0

Structure of Tyrphostin AG30
CAS No.: 122520-79-0

Chemical Structure| 122520-79-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tyrphostin AG 30 is an antimicrobial peptide with angiogenic properties. It activates human mast cells through the MAPK and NF-κB pathways.

Synonyms: AG30

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tyrphostin AG30

CAS No. :122520-79-0
Formula : C10H7NO4
M.W : 205.17
SMILES Code : O=C(O)/C(C#N)=C/C1=CC=C(O)C(O)=C1
Synonyms :
AG30
MDL No. :MFCD09739079
InChI Key :CJMWBHLWSMKFSM-XVNBXDOJSA-N
Pubchem ID :5328793

Safety of Tyrphostin AG30

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302+H312+H332-H315-H319
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312+P330-P302+P352+P312+P362+P364-P304+P340+P312-P305+P351+P338+P337+P313-P501

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

In Vitro:

Cell Line
Concentration Treated Time Description References
Human aortic endothelial cells (HAEC) 0.1, 1.0, 10 μg/ml 1, 2, 4 days To evaluate the effect of AG-30 on endothelial cell growth, results showed AG-30 increased MTS activity in a dose-dependent manner and was more potent than LL-37. J Cell Mol Med. 2009 Mar;13(3):535-46
Human aortic smooth muscle cells (HASMC) 0.1, 1.0, 10 μg/ml 1, 3, 5 days To evaluate the effect of AG-30 on smooth muscle cell growth, results showed AG-30 increased MTS activity in a dose-dependent manner. J Cell Mol Med. 2009 Mar;13(3):535-46
Human aortic endothelial cells (HAEC) 10 μg/ml 24 hours To evaluate the effect of AG-30 on endothelial cell migration, results showed AG-30 significantly increased cell migration. J Cell Mol Med. 2009 Mar;13(3):535-46
RBL-2H3 cells 0.1 – 1.5 µM 30 minutes AG-30/5C induces dose-dependent degranulation in RBL-2H3 cells stably expressing MRGPRX2, but native RBL-2H3 cells do not respond to AG-30/5C. J Immunol. 2019 Feb 15;202(4):1229-1238
LAD2 cells 0.01 – 1.5 µM 30 minutes AG-30/5C induces degranulation in LAD2 cells via MRGPRX2 with an EC50 value of <0.1 μM and maximal response at 1.0 −1.5 μM. J Immunol. 2019 Feb 15;202(4):1229-1238
Human aortic endothelial cells (HAEC) 0.1, 1.0, 10 μg/ml 4 hours To evaluate the chemotactic migration effect of AG-30 on endothelial cells, results showed AG-30 had chemotactic action. J Cell Mol Med. 2009 Mar;13(3):535-46
Human umbilical vein endothelial cells (HUVECs) 10 μg/ml 48 hours Evaluate the effect of AG30/5C on HUVECs proliferation, results showed AG30/5C significantly increased HUVECs proliferation. PLoS One. 2014 Mar 27;9(3):e92597
Human aortic endothelial cells (HAEC) 0.1, 1.0, 10 μg/ml 7 days To evaluate the effect of AG-30 on endothelial tube formation, results showed AG-30 promoted tube formation more effectively than LL-37 or control peptide. J Cell Mol Med. 2009 Mar;13(3):535-46
Human epidermal keratinocytes cell line (HaCaT cells) 0, 0.1, 1, and 10 μg/ml Second day AG30/5C induced cell growth of HaCaT cells in a dose-dependent manner. J Cell Mol Med. 2012 Jul;16(7):1629-39

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 male mice Ischemic hind limb model Intramuscular injection 100 μg, 500 μg Single injection, lasted for 28 days To evaluate the angiogenic effect of AG-30 in ischemic hind limb model, results showed AG-30 significantly increased blood flow and capillary density. J Cell Mol Med. 2009 Mar;13(3):535-46
Mice Diabetic mouse wound-healing model Topical application 100 μg/ml Repeated on days 0, 2, 4, 7, 9, 11, 14, and 16 after operation The topical application of AG30/5C accelerated wound healing with increased angiogenesis and attenuated MRSA infection. J Cell Mol Med. 2012 Jul;16(7):1629-39
SKHAV transgenic mice ΛsupFG1 shuttle-reporter transgenic mice Intradermal injection 50μg Injections on days 1 and 3, tissue harvested 10 days after the last treatment In hairless mice, AG30 introduced gene modifications in both tail and back skin via intradermal delivery, with mutation frequencies 4-fold higher than PBS controls. J Invest Dermatol. 2013 Mar;133(3):685-691

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.87mL

0.97mL

0.49mL

24.37mL

4.87mL

2.44mL

48.74mL

9.75mL

4.87mL

References

 

Historical Records

Categories